These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 3595648)

  • 1. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis.
    Prince MI; Burt AD; Jones DE
    Gut; 2002 Mar; 50(3):436-9. PubMed ID: 11839728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antituberculosis drug-induced hepatotoxicity in children.
    Donald PR
    Pediatr Rep; 2011 Jun; 3(2):e16. PubMed ID: 21772953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
    Durand F; Jebrak G; Pessayre D; Fournier M; Bernuau J
    Drug Saf; 1996 Dec; 15(6):394-405. PubMed ID: 8968694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulminant hepatitis during treatment with rifampicin, pyrazinamid and ethambutol.
    van Aalderen WM; Knoester H; Knol K
    Eur J Pediatr; 1987 May; 146(3):290-1. PubMed ID: 3595648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.
    Girling DJ
    Tubercle; 1978 Mar; 59(1):13-32. PubMed ID: 345572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enlarged cervical lymph nodes and elevated liver chemistry tests: a therapeutic dilemma.
    Dietrich CG; Gartung C; Lorenzen J; Geier A; Wasmuth HE; Matern S; Lammert F
    Ann Hepatol; 2004; 3(3):118-20. PubMed ID: 15505599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pyrazinamide versus ethambutol in short-term therapy of lung tuberculosis. A randomized study].
    Fiala W; Häcki MA; Brändli O
    Schweiz Med Wochenschr; 1983 Dec; 113(51):1956-9. PubMed ID: 6658432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
    Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
    Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Jaundice during treatment with rifampicin (12 cases)].
    Lesobre R; Ruffino J; Teyssier L; Achard F; Brefort G
    Rev Tuberc Pneumol (Paris); 1969; 33(3):393-403. PubMed ID: 5383009
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatotoxicity in rifampin-isoniazid treated patients related to their rate of isoniazid inactivation.
    Smith J; Tyrell WF; Gow A; Allan GW; Lees AW
    Chest; 1972 Jun; 61(6):587-8. PubMed ID: 5032153
    [No Abstract]   [Full Text] [Related]  

  • 12. [Jaundice and rifampicin. Critical study].
    Nebout T; Dhumeaux D; Berthelot P
    Nouv Presse Med; 1974 Mar; 3(12):733-6. PubMed ID: 4836507
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatotoxicity of rifampicin and isoniazid in children.
    Casteels-Van Daele M; Igodt-Ameye L; Corbeel L; Eeckels R
    J Pediatr; 1975 May; 86(5):739-41. PubMed ID: 1079531
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.